Share
5,887 Posts.
lightbulb Created with Sketch. 226
clock Created with Sketch.
14/05/16
17:28
Share
Originally posted by welchdave4a
↑
not a serious competitor in my opinion
1. Needs FDA approval to be a serious competitor
2. Requires a purchase of device
3. Clinician would be wary of diagnosing from an "off the shelf gadget"
4. Resapp scope of disease diagnosis and management will only increase
5 Resapp can distinguish between what type of pneumonia, with preliminary results for separation of bacterial and atypical pneumonia from viral pneumonia with accuracy of 89% and 92% respectively
6. I believe they will approach FDA approval for numerous diseases once the initial application has been completed. For the diagnosis of croup, viral pneumonia, bronchiolitis and upper respiratory tract infections (URTIs) ResApp’s algorithms achieved accuracy levels between 90% and 98% on the larger dataset.
Now they have the funds its only a matter of time Resapp have application for CE Mark for Europe and Asia is next.....
Expand
Originally posted by Pierre83
↑
Morning Martin,
Couple of quick Points..
1) The Stethoscope is a fantastic piece of equipment that has helped saved Millions of lives.. no doubt about it.
2) In regards to it's sole use in diagnosing Pneumonia it does not do the job. Below are some facts.
"CAP Pnuemonia is diagnosed by assessing symptoms, making a physical examination and on x-ray. Other tests, such as sputum examination, supplement chest x-rays"
""A cornerstone of diagnosis is the chest x-ray, which is recommended for diagnosis in every circumstance and usually reveals an infiltrate (Fig. 2) at presentation. However, this finding may be absent in the dehydrated patient. Also, the radiographic manifestations of chronic diseases such as congestive heart failure, chronic obstructive pulmonary disease (COPD), and malignancy can obscure the infiltrate of pneumonia."
3) And finally...
"ResApp Achieves Breakthrough Performance
in Paediatric Clinical Study"
"Correctly detected lower respiratory tract disease in 97% of patients
who were initial diagnosed as clear by experienced clinicians using
stethoscopes (an increase from the 80% reported previously)"
Expand
Both products are aids for diagnosing disease. Resapp will initially be approved to diagnose pneumonia and asthma. The other product will be used as a step in diagnosing many more diseases, including pneumonia and asthma. Therefore, it is a competitor. And what's more, a telehealth provider is actually partnering with that company. Not saying one product is better than the other. But we can't just dismiss it.
It's best to be open-minded about competition and to look at things from the telehealth providers' perspective, not from our perspective as shareholders of RAP. Telehealth providers want to keep both patients and doctors happy, and they will navigate the territory in their own best interests.